Unknown

Dataset Information

0

Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT.

ABSTRACT: BACKGROUND:Acute myeloid leukemia (AML) is both more common and with more biologically aggressive phenotype in the elderly. Allogenic stem cell transplantation (allo-SCT) is the best treatment option in fit patients. Either HLA-matched unrelated donor (MUD) or haploidentical (Haplo) donor are possible alternative for patients in need. METHODS:We retrospectively compared non-T-cell-depleted Haplo (n?=?250) to 10/10 MUD (n?=?2589) in AML patients ??60 years. RESULTS:Median follow-up was 23 months. Disease status at transplant differs significantly between the two groups (p?

SUBMITTER: Santoro N 

PROVIDER: S-EPMC5902953 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT.

Santoro Nicole N   Labopin Myriam M   Giannotti Federica F   Ehninger Gerard G   Niederwieser Dietger D   Brecht Arne A   Stelljes Matthias M   Kröger Nicolaus N   Einsele Herman H   Eder Matthias M   Hallek Michael M   Glass Bertram B   Finke Jürgen J   Ciceri Fabio F   Mohty Mohamad M   Ruggeri Annalisa A   Nagler Arnon A  

Journal of hematology & oncology 20180416 1

<h4>Background</h4>Acute myeloid leukemia (AML) is both more common and with more biologically aggressive phenotype in the elderly. Allogenic stem cell transplantation (allo-SCT) is the best treatment option in fit patients. Either HLA-matched unrelated donor (MUD) or haploidentical (Haplo) donor are possible alternative for patients in need.<h4>Methods</h4>We retrospectively compared non-T-cell-depleted Haplo (n = 250) to 10/10 MUD (n = 2589) in AML patients ≥ 60 years.<h4>Results</h4>Median fo  ...[more]

Similar Datasets

Unknown Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT.
| S-EPMC6610936 | biostudies-literature
Unknown Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT.
| S-EPMC5855999 | biostudies-literature
Unknown Post-transplant cyclophosphamide containing regimens after matched sibling, matched unrelated and haploidentical donor transplants in patients with acute lymphoblastic leukemia in first complete remission, a comparative study of the ALWP of the EBMT.
| S-EPMC8161915 | biostudies-literature
Unknown Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia.
| S-EPMC4543223 | biostudies-literature
Unknown Alternative donor transplantation for acute myeloid leukemia in patients aged ?50 years: young HLA-matched unrelated or haploidentical donor?
| S-EPMC7012481 | biostudies-literature
Unknown Unmanipulated haploidentical stem cell transplantation in adults with acute lymphoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT.
| S-EPMC5450162 | biostudies-literature
Unknown Haploidentical Versus Matched Unrelated Donor Transplants Using Post-Transplantation Cyclophosphamide for Lymphomas.
| S-EPMC10316698 | biostudies-literature
Unknown Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.
| S-EPMC10152475 | biostudies-literature
Unknown Haploidentical vs matched unrelated donors for patients with ALL: donor age matters more than donor type.
| S-EPMC10139863 | biostudies-literature
Unknown Haploidentical transplantation in primary refractory/relapsed secondary vs de novo AML: from the ALWP/EBMT.
| S-EPMC11372397 | biostudies-literature